Bosutinib belongs to which generation of TKI and an introduction to its pharmacological characteristics

Bosutinib is an oral tyrosine kinase inhibitor (TKI) that is classified as a second-generation TKI The drug is mainly used to treat chronic myelogenous leukemia (CML), especially patients who are resistant or intolerant to imatinib (Imatinib). As a second-generation TKI, bosutinib has been optimized in structure and mechanism of action, has stronger inhibitory ability and wider mutation target coverage, and is an important alternative treatment option.

Pharmacologically, bosutinib mainly targets the kinase activity of the BCR-ABL fusion protein, which is one of the core driving factors in the pathogenesis of CML. Compared with the first generation TKI, bosutinib has a stronger inhibitory effect on a variety of BCR-ABL mutants, especially in some patients with imatinib-resistant mutants. It still shows good efficacy. At the same time, bosutinib can also inhibit the Src family kinases and have a certain impact on the migration and proliferation of tumor cells.

Compared with other second-generation TKIs (such as dasatinib and nilotinib), bosutinib has certain advantages in target selectivity. It is highly specific for the ABL target, but has a weaker effect on PDGFR and KIT and other non-targets, thereby reducing the probability of some non-target side effects. This makes bosutinib better tolerated in some patients and suitable for long-term use.

In general, bosutinib, as a second-generation TKI, provides a wider range of mutation response capabilities and better safety in the treatment of CML. Its unique pharmacological characteristics and clinical manifestations provide new treatment options for patients after imatinib failure. Before use, a professional doctor still needs to evaluate the patient's specific condition and conduct corresponding mutation testing to formulate the most appropriate individualized treatment plan.

Reference materials:https://www.drugs.com/